ARS Pharmaceuticals (SPRY) Short Interest Ratio & Short Volume $14.88 0.00 (0.00%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$14.98 +0.09 (+0.64%) As of 04/17/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARS Pharmaceuticals Short Interest DataARS Pharmaceuticals (SPRY) has a short interest of 17.15 million shares, representing 30.60% of the float (the number of shares available for trading by the public). This marks a -11.73% decrease in short interest from the previous month. The short interest ratio (days to cover) is 10.4, indicating that it would take 10.4 days of the average trading volume of 1.15 million shares to cover all short positions.Current Short Interest17,150,000 sharesPrevious Short Interest19,430,000 sharesChange Vs. Previous Month-11.73%Dollar Volume Sold Short$215.75 millionShort Interest Ratio10.4 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares98,120,000 sharesFloat Size56,040,000 sharesShort Percent of Float30.60%Today's Trading Volume1,550,196 sharesAverage Trading Volume1,152,140 sharesToday's Volume Vs. Average135% Short Selling ARS Pharmaceuticals? Sign up to receive the latest short interest report for ARS Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSPRY Short Interest Over TimeSPRY Days to Cover Over TimeSPRY Percentage of Float Shorted Over Time ARS Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202517,150,000 shares $215.75 million -11.7%30.6%10.4 $12.58 3/15/202519,430,000 shares $230.63 million +2.3%37.5%12.5 $11.87 2/28/202519,000,000 shares $199.12 million +15.3%37.0%14.4 $10.48 2/15/202516,480,000 shares $198.09 million +12.3%32.1%13.1 $12.02 1/31/202514,670,000 shares $191.00 million -1.0%29.1%11 $13.02 1/15/202514,810,000 shares $177.87 million +8.3%29.0%11.6 $12.01 12/31/202413,680,000 shares $144.32 million +8.1%26.8%11.7 $10.55 12/15/202412,660,000 shares $150.65 million -7.1%24.8%11.6 $11.90 11/30/202413,630,000 shares $197.77 million -1.6%26.8%13 $14.51 11/15/202413,850,000 shares $194.04 million +9.9%27.3%12.9 $14.01 Get the Latest News and Ratings for SPRY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/31/202412,600,000 shares $185.47 million +5.7%25.6%10.5 $14.72 10/15/202411,920,000 shares $181.54 million +7.4%24.2%10.5 $15.23 9/30/202411,100,000 shares $160.95 million -4.6%22.7%10.1 $14.50 9/15/202411,640,000 shares $154.81 million +6.2%23.8%10.4 $13.30 8/31/202410,960,000 shares $142.26 million -9.2%22.5%10.5 $12.98 8/15/202412,070,000 shares $163.43 million +21.6%25.3%12.9 $13.54 7/31/20249,930,000 shares $107.94 million +13.6%20.9%15.7 $10.87 7/15/20248,740,000 shares $101.91 million +27.0%18.4%15.3 $11.66 6/30/20246,880,000 shares $58.55 million +0.4%14.5%12.5 $8.51 6/15/20246,850,000 shares $59.32 million +0.4%14.5%12.7 $8.66 5/31/20246,820,000 shares $60.56 million -0.7%15.0%11.5 $8.88 5/15/20246,870,000 shares $61.01 million +7.7%16.1%10.1 $8.88 4/30/20246,380,000 shares $55.51 million +4.8%15.8%9 $8.70 4/15/20246,090,000 shares $56.27 million +10.7%14.4%9 $9.24 3/31/20245,500,000 shares $56.21 million +29.4%13.1%8.5 $10.22 3/15/20244,250,000 shares $38.93 million -7.8%10.2%7.3 $9.16 2/29/20244,610,000 shares $38.59 million -5.1%11.2%10 $8.37 2/15/20244,860,000 shares $35.28 million No Change11.8%11.3 $7.26 1/31/20244,860,000 shares $30.18 million -30.0%11.8%11.4 $6.21 1/15/20246,940,000 shares $41.02 million -0.4%16.9%13.8 $5.91 12/31/20236,970,000 shares $38.20 million +4.3%16.9%12.6 $5.48 12/15/20236,680,000 shares $34.80 million +10.8%16.2%9.3 $5.21 11/30/20236,030,000 shares $29.12 million +1.5%14.7%4.4 $4.83 11/15/20235,940,000 shares $26.91 million -10.0%14.6%4.3 $4.53 10/31/20236,600,000 shares $23.56 million +16.4%16.2%5 $3.57 10/15/20235,670,000 shares $21.15 million -3.4%14.0%4.6 $3.73 9/30/20235,870,000 shares $22.19 million +1.6%14.5%4.9 $3.78 9/15/20235,780,000 shares $41.96 million +7.6%14.2%5.1 $7.26 8/31/20235,370,000 shares $38.07 million -7.7%10.4%10.2 $7.09 8/15/20235,820,000 shares $40.97 million -4.1%12.2%9.7 $7.042025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis (Ad)What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years. Click here to see Dan's full warning to the public. 7/31/20236,070,000 shares $44.61 million -2.7%12.8%3.7 $7.35 7/15/20236,240,000 shares $42.62 million +5.2%13.1%3.8 $6.83 6/30/20235,930,000 shares $39.73 million +9.4%12.5%3.7 $6.70 6/15/20235,420,000 shares $32.79 million +22.4%11.4%3.4 $6.05 5/31/20234,430,000 shares $30.83 million +22.4%9.4%3 $6.96 5/15/20233,620,000 shares $28.27 million No Change7.7%2.7 $7.81 SPRY Short Interest - Frequently Asked Questions What is ARS Pharmaceuticals' current short interest? Short interest is the volume of ARS Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 17,150,000 shares of SPRY short. 30.60% of ARS Pharmaceuticals' shares are currently sold short. Learn More on ARS Pharmaceuticals' current short interest. What is a good short interest ratio for ARS Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SPRY shares currently have a short interest ratio of 10.0. Learn More on ARS Pharmaceuticals's short interest ratio. Which institutional investors are shorting ARS Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ARS Pharmaceuticals: Wolverine Trading LLC, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, Susquehanna International Group LLP, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for ARS Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 30.60% of ARS Pharmaceuticals' floating shares are currently sold short. Is ARS Pharmaceuticals' short interest increasing or decreasing? ARS Pharmaceuticals saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 17,150,000 shares, a decrease of 11.7% from the previous total of 19,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is ARS Pharmaceuticals' float size? ARS Pharmaceuticals currently has issued a total of 98,120,000 shares. Some of ARS Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ARS Pharmaceuticals currently has a public float of 56,040,000 shares. How does ARS Pharmaceuticals' short interest compare to its competitors? 30.60% of ARS Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ARS Pharmaceuticals: Sarepta Therapeutics, Inc. (6.92%), Blueprint Medicines Co. (8.82%), Axsome Therapeutics, Inc. (13.61%), Krystal Biotech, Inc. (10.97%), Nuvalent, Inc. (13.24%), Grifols, S.A. (1.15%), Elanco Animal Health Incorporated (3.32%), Verona Pharma plc (12.00%), ADMA Biologics, Inc. (5.69%), Cytokinetics, Incorporated (12.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short ARS Pharmaceuticals stock? Short selling SPRY is an investing strategy that aims to generate trading profit from ARS Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ARS Pharmaceuticals? A short squeeze for ARS Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SPRY, which in turn drives the price of the stock up even further. How often is ARS Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SPRY, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies Sarepta Therapeutics Short Interest Data Blueprint Medicines Short Interest Data Axsome Therapeutics Short Interest Data Krystal Biotech Short Interest Data Nuvalent Short Interest Data Grifols Short Interest Data Elanco Animal Health Short Interest Data Verona Pharma Short Interest Data ADMA Biologics Short Interest Data Cytokinetics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SPRY) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.